Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network
Sponsor: European Myeloma Network B.V.
Listed as NCT01046006, this PHASE2 trial focuses on Waldenstrom's Macroglobulinemia and remains completed. Sponsored by European Myeloma Network B.V., it has been updated 8 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE2
-
May 2021 — Mar 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 3 earlier versions
-
Jan 2021 — May 2021 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Myeloma Network B.V.
- Meletios A. Dimopoulos
For direct contact, visit the study record on ClinicalTrials.gov .